New restrictions and safety checks on online pharmacies that prescribing high risk drugs, such as the weight loss drugs semaglutide and tirzepatide, could have a “significant” impact on GPs’ workload, ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Groundbreaking research reveals how a popular diabetes and weight loss medication might offer unexpected help for those dealing with alcohol challenges.

Court rulings against parts of Donald Trump's agenda put White House officials on the defensive. Hamas says it will not ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

There's growing evidence to suggest that GLP-1 drugs, which include Ozempic's semaglutide, may be useful for treating alcohol ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...